Research

Published Research

Breaking Gridlock: The Determinants of Health Policy Change in Congress

Authors: Craig Volden, Alan E. Wiseman

Scholars have often commented that health policymaking in Congress is mired in political gridlock, that reforms are far more likely to fail than to succeed, and the path forward is unclear. To reach such conclusions, scholars of health politics have tended to analyze individual major reform proposals to determine why they succeeded or failed and what lessons could be drawn for the future. 

Learn more
Published Research

The Strength of Graduated Drivers License Programs and Fatalities among Teen Drivers and Passengers

Authors: M.A. Morrisey, D.C. Grabowski, T. S. Dee, C. Campbell

Objectives

The purpose of this study is to investigate the effects of differentially stringent graduated drivers license programs on teen driver fatalities, day-time and night-time teen driver fatalities, fatalities of teen drivers with passengers present, and fatalities among teen passengers

Learn more
Published Research

Graduated Driver Licensing and Teen Traffic Fatalities

Authors: Dee Thomas, David C. Grabowski, Michael A. Morrisey

Over the last 8 years, nearly every state has introduced graduated driver licensing (GDL) for teens. These new licensing procedures require teen drivers to advance through distinct stages where they are subject to a variety of restrictions (e.g., adult supervision, daytime driving, passenger limits).

Learn more
Published Research

Napsterizing Pharmaceuticals: Access, Innovation, and Welfare

Authors: James W. Hughes, Michael J. Moore, Edward A. Snyder

We analyze the effects on consumers of an extreme policy experiment – Napsterizing’ pharmaceuticals – whereby all patent rights on branded prescription drugs are eliminated for both existing and future prescription drugs without compensation to the patent holders. The question of whether this policy maximizes consumer welfare cannot be resolved on an a priori basis due to an obvious tradeoff: While accelerating generic entry will yield substantial gains in consumer surplus associated with greater access to the current stock of pharmaceuticals, future consumers will be harmed by reducing the flow of new pharmaceuticals to the market. 

Learn more